| Diagnostic tumor markers and their role in the management of specific childhood cancers (DNB 2020/1)5 | 542 | 2020 |
| Define tumour lysis syndrome. Enlist its important constituents. Outline its etiology and describe the management (DNB 2008/1)10 | 543 | 2008 |
| Outline the essential components and pathophysiology of tumor lysis syndrome. Describe its management (DNB 2011/1)2+4+4 | 543 | 2011 |
| Define tumour lysis syndrome. Describe the pathophysiology of tumour lysis syndrome. How will you prevent occurrence of tumour lysis syndrome? (DNB 2011/2)2+4+4 | 543 | 2011 |
| Enumerate the oncological emergencies occurring in leukmia/lymphomas (DNB 2016/1)2 | 543 | 2016 |
| Treatment of tumour lysis syndrome (DNB 2017/2)6 | 543 | 2017 |
| Treatment of tumour lysis syndrome (DNB 2018/1)5 | 543 | 2018 |
| Tumour lysis syndrome (DNB 2019/2)5 | 543 | 2019 |
| Metabolic emergencies in pediatric malignancies (DNB 2020/1)5 | 543 | 2020 |
| Enumerate oncological emergencies in newly diagnosed case of acute leukemia (DNB 2022/1)5 | 543 | 2022 |
| Management of tumour lysis syndrome (DNB 2023/1)5 | 543 | 2023 |
| Management of Tumor lysis syndrome (DCH 2023/2)5 | 543 | 2023 |
| Tumour lysis syndrome (DCH 2024/1)5 | 543 | 2024 |
| Management of CNS Leukemia (DNB 1996/1)14 | 544 | 1996 |
| Treatment and prognosis of ALL (DNB 1997/2)15 | 544 | 1997 |
| Management of a case of ALL in a 3-year-old (DNB 2003/1)25 | 544 | 2003 |
| Discuss management of a child with acute leukemia (DNB 2006/1)10 | 544 | 2006 |
| Management of a child with acute leukemia (DNB 2006/2)10 | 544 | 2006 |
| Prognostic indicators in Acute Leukemia (DNB 2007/2)10 | 544 | 2007 |
| Utility of immunophenotyping in the diagnosis of leukemia in children. Outline the treatment of acute lymphoblastic leukemia (DNB 2009/2)4+6 | 544 | 2009 |
| a) Classification of childhood leukemias b) Management of Tumor lysis syndrome (DNB 2014/2)5+5 | 544 | 2014 |
| Management of Acute Myeloid Leukemia (DNB 2016/1)5 | 544 | 2016 |
| Risk stratification in ALL in children (DNB 2016/2)5 | 544 | 2016 |
| Treatment of CML (DNB 2016/2)5 | 544 | 2016 |
| Utility of immunophenotyping in the diagnosis of ALL (DNB 2017/1)5 | 544 | 2017 |
| Outline management of ALL (DNB 2017/1)5 | 544 | 2017 |
| Treatment of standard risk acute lymphoblastic leukemia (DNB 2018/1)5 | 544 | 2018 |
| Role of immunophenotyping in diagnosis of acute leukemia (DNB 2018/2)5 | 544 | 2018 |
| Risk stratification in ALL in children (DNB 2020/2)5 | 544 | 2020 |
| Acute Lymphoblastic Leukemia - cytogenetics and risk stratification (DNB 2021/2)5 | 544 | 2021 |
| Cytogenetics in acute leukemia (DNB 2022/2)5 | 544 | 2022 |
| Risk stratification of a newly diagnosed acute lymphatic leukemia (DNB 2023/1)5 | 544 | 2023 |
| Molecular diagnostic parameters in the diagnosis of acute myeloid leukemia (DNB 2023/1)5 | 544 | 2023 |
| Immunophenotyping of acute leukaemia (DCH 2023/2)5 | 544 | 2023 |
| Juvenile myelomonocytic leukemia (JMML) (DNB 2023/2)5 | 544 | 2023 |
| Treatment and prognosis of acute myeloid leukemia in children (DNB 2024/1)5 | 544 | 2024 |
| Risk stratification of acute leukemia (DNB 2024/2)5 | 544 | 2024 |
| Chronic leukemia in children: a) Classification b) Immunophenotyping c) Risk stratification d) Management (DCH 2024/2)2+2+2+4 | 544 | 2024 |
| Different types of Lymphomas in children and their Histopathological classification (DNB 1993/2)15 | 545 | 1993 |
| Hodgkin's Lymphomas - Pathophysiology (DNB 2021/2)5 | 545 | 2021 |
| Diagnosis and management of acute mediastinal syndrome (DNB 2022/2)5 | 545 | 2022 |
| Staging of Hodgkin's disease (DNB 2024/1)5 | 545 | 2024 |
| Staging of Hodgkin's lymphoma (DNB 2024/2)5 | 545 | 2024 |
| Clinical features and diagnosis of posterior fossa tumours (DNB 2018/1)5 | 546 | 2018 |
| Supratentorial intracranial tumors in children (DNB 2020/2)5 | 546 | 2020 |
| Neuroblastoma- diagnosis and clinical features (DNB 2018/2)5 | 547 | 2018 |
| Treatment of Neuroblastoma (DNB 2020/1)5 | 547 | 2020 |
| Clinical manifestations of neuroblastoma (DNB 2024/1)5 | 547 | 2024 |
| Clinical presentation and management of Wilms tumour (DNB 2019/1)5 | 548 | 2019 |
| Clinical presentation and diagnosis of Ewing's sarcoma (DNB 2023/2)5 | 550 | 2023 |
| Write in brief the clinical manifestations, laboratory findings and management principles of Langerhans Cell Histocytosis (DNB 2009/1)10 | 556 | 2009 |
| Classify childhood histiocytosis. Describe the clinical manifestations, diagnosis and treatment of Langerhan's cell histiocytosis (DNB 2010/1)3+3+2+2 | 556 | 2010 |
| How will you classify childhood Histiocytosis? Describe the diagnostic criteria, clinical manifestations and treatment for hemophagocytic lymphohistiocytosis. What are the infections associated with it? (DNB 2011/2)2+2+2+2+2 | 556 | 2011 |
| A) Classify childhood histiocytosis B) Clinical features and management of a case of Langerhan's cell histiocytosis (DNB 2015/1)3+3+4 | 556 | 2015 |
| Haemophagocytic Lymphohistiocytosis in children (DNB 2021/2)5 | 556 | 2021 |
| Haemophagocytic Lymphohistiocytosis in children (DNB 2022/1)5 | 556 | 2022 |
| Diagnostic criteria for Hemophagocytic Lymphohistiocytosis (HLH) (DNB 2024/1)5 | 556 | 2024 |
| Risk stratification in acute leukemia (DNB 2024/2)5 | 544 | 2024 |
| Staging of Hodgkin's lymphoma (DNB 2024/2)5 | 545 | 2024 |